Hemab Therapeutics Holdings, Inc. (COAG) stock
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.15+0.09 (+0.23%)
Close on Nov 18, 2026Market cap $1.83BP/E –Yield –
Hemab Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$29.76M | – |
| Q2 FY2026 | Jun 30, 2026 | -$26.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$23.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.56M | – |
See a number that looks wrong?